论文部分内容阅读
目的:探讨联合吸入沙美特罗替卡松与噻托溴铵对慢性阻塞性肺疾病的疗效。方法:将88例中重度COPD患者随机分为3组,采用分组对比治疗方法。结果:与同组治疗前相比,治疗后噻托溴铵组、沙美特罗替卡松组、联合治疗组第1秒用力呼气量显著提高(P<0.05),第1秒用力呼气容积/用力肺活量、第1秒用力呼气容积/预计值均较治疗前改善(P<0.05);联合治疗组第1秒用力呼气容积、第1秒用力呼气容积/用力肺活量、第1秒用力呼气容积/预计值改善优于沙美特罗替卡松组、噻托溴铵组,差异有统计学意义(P<0.05)。结论:沙美特罗替卡松粉吸入剂联合噻托溴铵粉吸入剂治疗慢性阻塞性肺疾病疗效肯定,优于单用一种药物治疗,值得临床进一步推广应用。
Objective: To investigate the efficacy of inhaled salmeterol and tiotropium on chronic obstructive pulmonary disease. Methods: Eighty-eight patients with moderate-to-severe COPD were randomly divided into three groups. The treatment groups were divided into two groups. Results: Compared with the same group before treatment, tiotropium group, salmeterol and ticagastrone group, combination therapy group forced expiratory volume of 1 second significantly increased (P <0.05), 1 second forced expiratory Volume / forced vital capacity, forced expiratory volume in 1 second / predicted value were improved compared with those before treatment (P <0.05); 1 second forced expiratory volume in the combined treatment group, forced expiratory volume in 1 second / forced vital capacity, Second forced expiratory volume / expected value is better than salmeterrosalginase group, tiotropium group, the difference was statistically significant (P <0.05). Conclusion: Salmeterol ticagrelor powder inhalation combined with tiotropium powder inhaler for the treatment of chronic obstructive pulmonary disease has a certain effect, which is better than that of single drug therapy, which is worth further clinical application.